Table 3. Multivariate analysis of p53 (50%) on PFS and OS in Dutch and Scottish patients (cohorts combined).

	PFS			OS
	P-value	HR	95% CI	P-value	HR	95% CI
Dutch cohorta	0.036	0.76	0.59–0.98	0.101	0.80	0.61–1.05
Age>58 years	0.31	1.13	0.89–1.44	0.072	1.27	0.98–1.63
Residual disease >2 cm	<0.001	1.97	1.52–2.57	<0.001	1.94	1.47–2.57
Non-serous tumour type	0.092	0.81	0.64–1.04	0.611	0.94	0.72–1.21
Stage III/IV	<0.001	2.14	1.45–3.17	<0.001	2.12	1.38–3.25
Grade II/III	0.001	2.53	1.45–4.44	0.001	2.65	1.46–4.79
Chemotherapy	<0.001			<0.001
Platinum vs taxane and platinum	0.237	0.86	0.67–1.10	0.004	0.67	0.51–0.88
Other vs platinum	<0.001	2.86	1.88–4.37	<0.001	2.46	1.61–3.73
Aberrant p53 staining	0.228	1.16	0.91–1.47	0.362	1.13	0.87–1.45

CI=confidence interval; HR=hazard ratio; OS=overall survival; PFS=progression-free survival.

^aCategories are given relative to the baseline comparator group.